Skip to main content
Fig. 5 | Alzheimer's Research & Therapy

Fig. 5

From: Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions

Fig. 5

Mirodenafil reduces Dkk1 expression levels, activating the Wnt/β-catenin signaling. A Western blot analysis B Real-time qRT-PCR and for Dkk1 after co-treatment with Aβ42 and mirodenafil in HT-22 cells. C Comparative western blot analysis of Dkk1 expression levels after co-treatment with Aβ and PDE5 inhibitors [mirodenafil(Mir), sildenafil(Sil), tadalafil (Tad), vardenafil (Vad)]. D Quantification of Dkk1 western blots after co-treatment with Aβ and PDE5 inhibitors. E TOPFLASH reporter gene assay was employed to measure the levels of the Wnt/β-catenin transcriptional activity after co-treatment with Aβ42 and mirodenafil in HT-22 cells. F Measurement of intracellular Ca2+ contents in human brain pericytes after co-treatment with H2O2 and mirodenafil (n = 9). Data are presented as the mean ± SEM; *P < 0.05, **P < 0.01, ****P < 0.0001. All statistical comparisons were performed relative to Aβ42-treated cells. Statistical significance was assessed by one-way ANOVA followed by Bonferroni’s post hoc test for multiple comparisons

Back to article page